Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia.

Autor: Zakalashvili M; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Zarkua J; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Weizenegger M; Medizinisches Versorgungszentrum Dr. Limbach & Kollegen, Heidelberg, Germany., Bartel J; Medizinisches Versorgungszentrum Dr. Limbach & Kollegen, Heidelberg, Germany., Raabe M; Medizinisches Versorgungszentrum Dr. Limbach & Kollegen, Heidelberg, Germany., Zangurashvili L; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Kankia N; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Jashiashvili N; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Lomidze M; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Telia T; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Kerashvili V; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Zhamutashvili M; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Abramishvili N; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Hedskog C; Gilead Sciences, Inc., Foster City, CA, USA., Chodavarapu K; Gilead Sciences, Inc., Foster City, CA, USA., Brainard DM; Gilead Sciences, Inc., Foster City, CA, USA., McHutchison JG; Gilead Sciences, Inc., Foster City, CA, USA., Mo H; Gilead Sciences, Inc., Foster City, CA, USA., Svarovskaia E; Gilead Sciences, Inc., Foster City, CA, USA., Gish RG; Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA., Rtskhiladze I; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia., Metreveli D; Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia.
Jazyk: angličtina
Zdroj: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2018 Mar; Vol. 38 (3), pp. 451-457. Date of Electronic Publication: 2017 Sep 02.
DOI: 10.1111/liv.13540
Abstrakt: Background and Aims: This study aimed to evaluate the prevalence of the hepatitis C virus intergenotype recombinant strain RF1_2k/1b in Georgia, confirm viral recombination by full genome sequencing, and determine a genetic relationship with previously described recombinant hepatitis C viruses.
Methods: We retrospectively analysed data from 1421 Georgian patients with chronic hepatitis C. Genotyping was performed with the INNO-LiPA VERSANT HCV Genotype 2.0 Assay.
Results: Virus isolates were assigned to nonspecific hepatitis C genotypes 2a/2c (n = 387) as performed by sequencing of core and NS5B genes. Subsequently, sequencing results classified the core region as genotype 2k and the NS5B region as genotype 1b for 72% (n = 280) of genotype 2 patients, corresponding to 19.7% of hepatitis C patients in Georgia. Eight samples were randomly selected for full genome sequencing which was successful in 7 of 8 samples. Analysis of the generated consensus sequences confirmed that all 7 viruses were 2k/1b recombinants, with the recombination breakpoint located within 73-77 amino acids before the NS2-NS3 junction, similar to the previously described RF1_2k/1b virus. Phylogenetic analysis revealed clustering of the Georgian 2k/1b viruses and RF1_2k/1b, suggesting that they are genetically related.
Conclusions: The 19.7% prevalence of RF1_2k/1b in Georgia patients is far higher than has generally been reported to date worldwide. Identification of recombinants in low income countries with a high prevalence of HCV infection might be reasonable for choosing the most cost-effective treatment regimens.
(© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje